 |
|
| Type | Public (NYSE: BDX) |
|---|---|
| Founded | East Rutherford, New Jersey U.S. (1897) |
| Founder(s) | Maxwell Becton and Fairleigh S. Dickinson |
| Headquarters | Franklin Lakes, New Jersey, USA |
| Number of locations | 12 U.S. locations |
| Area served | Worldwide |
| Key people | Edward J. Ludwig Chairman, President and CEO |
| Industry | Medical Instruments & Supplies |
| Products | Syringes, Bandages |
| Revenue | US$6,359,708 (FY ending September 30, 2007) |
| Operating income | US$1,203,200 |
| Net income | US$890,033 |
| Total assets | US$3,130,600 |
| Total equity | US$4,361,957 |
| Employees | 28,030 Worldwide |
| Website | http://www.bd.com/ |
Becton, Dickinson and Company (BD) (NYSE: BDX), is a medical technology company that manufactures and sells medical devices, instrument systems and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD does business in nearly 50 countries with its 27,000 employees.[1] The company's customers include healthcare institutions, life science researchers, clinical laboratories, industry and the general public. The company was started by Maxwell Becton and Fairleigh S. Dickinson.[2] In fiscal year 2006, BD revenues grew 8% to $5.83 billion worldwide.[3] In October 2008, BD Canada Inc. was named one of "Canada's Top 100 Employers" by Mediacorp Canada Inc., and was featured in Maclean's newsmagazine. Later that month, BD Canada Inc. was also named one of Greater Toronto's Top Employers, which was announced by the Toronto Star newspaper.[4]
Contents |
BD comprises three business segments: BD Medical, BD Diagnostics and BD Biosciences.
BD Medical is among the world's leading suppliers of medical devices and a leading innovator in injection- and infusion-based drug delivery since 1906, when the Company built the first-ever facility in the U.S. to manufacture needles and syringes. The BD Medical segment is focused on providing innovative solutions to reduce the spread of infection, enhance diabetes treatment, advance drug delivery and improve ophthalmic surgery outcomes. [1]
BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to accurately detect a broad range of infectious diseases, healthcare-associated infections (HAIs) and cancers. The BD Diagnostics segment focuses on improving health outcomes for patients and providing laboratories with solutions that improve quality, enhance laboratory system productivity, reduce costs and inform medical decisions. [2]
BD Biosciences is a world leader in bringing innovative diagnostic and research tools to life scientists, clinical researchers, laboratory professionals and clinicians who are involved in basic research, drug discovery and development, biopharmaceutical production and disease management. The BD Biosciences segment is focused on continually advancing the science and applications associated with cellular analysis and products that help grow living cells and tissue. [3]
More information can be found in BD's 2008 Annual Report. [4]
Acquisitions: BD has grown during its 111-year history both organically and through acquisitions. On February 14, 2006 BD announced its acquisition of GeneOhm Sciences, Inc.[5], a company that develops diagnostic testing for bacteria, for $230 million and up to $25 million in additional incentives. A more comprehensive list of acquisitions can be found on BD's History page. [5]
The Environmental Protection Agency has named Becton Dickinson a potentially responsible party in at least nine Superfund toxic waste sites.[6]
In mid 2007, the firm's "BD Discardit II" series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes which were alleged to have been from this series.[7] The newspaper Dziennik Online claimed that other series such as 06022444, 0603266 and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. [6] Legal proceedings related to the incident started in December 2006.[7] According to an article published in Dziennik on Monday, 21 April 2008, the prosecutor’s office in Lublin discontinued the inquiry because the disposable syringes were not dangerous.
|
|
Wikis
Search
